Evidence map›Paper›PMID 35179959›Full record

ArticleScience advances2022

Chenkui Miao, Takuya Tsujino, Tomoaki Takai, Fu Gui, Takeshi Tsutsumi, Zsofia Sztupinszki, Zengjun Wang, Haruhito Azuma, Zoltan Szallasi, Kent W Mouw and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. RNASEH2B loss and PARP inhibition in advanced prostate cancer.The Journal of clinical investigation · 2024
    Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Potential promising of synthetic lethality in cancer research and treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Chenkui MiaoDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6748-022X
Takuya TsujinoDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1559-1889
Tomoaki TakaiDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Fu GuiDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8329-7118
Takeshi TsutsumiDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6144-9464
Zsofia SztupinszkiComputational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-8691-4086
Zengjun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Haruhito AzumaDepartment of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Zoltan SzallasiComputational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0001-5395-7509
Kent W MouwDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7939-7343
Lee ZouDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3094-1058
Adam S KibelDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9446-7781
Li JiaDivision of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4017-1157
Brigham and Women's Hospital · USBoston Children's Hospital · USHarvard University · USJiangsu Province Hospital · CNOsaka University of Pharmaceutical Sciences · JP

Funding

Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancerR01CA262524 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JIA, LI · 2021 to 2025
$2.0M
RNASEH2B loss to predict response to PARP inhibitor in prostate cancerR21CA252578 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JIA, LI · 2021 to 2022
$456k
NCI NIH HHS R01 CA262524NCI NIH HHS R21 CA252578
6 · The paper itself

Abstract

Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsProstatic NeoplasmsBRCA2 ProteinDNA RepairDNA ReplicationGenes, BRCA2HumansMaleRetinoblastoma Binding ProteinsRibonuclease HUbiquitin-Protein LigasesBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsRB1 protein, humanRetinoblastoma Binding ProteinsRibonuclease Hribonuclease HIIUbiquitin-Protein Ligases

Identifiers

PMID35179959
PMCPMC8856618
OpenAlexW4220868364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.